GlassScriptPhysician profile
Jayce G Cook
NPI 1700225976
$1,302.27
in general payments reported to CMS, 2019-2025
22 companies · $533 in 2025
The $533 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $379 · 2024: $391 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $183.73 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $145.64 | 2023-2025 | Vraylar |
| Pfizer INC. | $134.67 | 2023-2025 | |
| Lilly USA, LLC | $127.94 | 2023-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $105.16 | 2024-2025 | Airsupra, Farxiga |
| Sumitomo Pharma America, INC. | $77.69 | 2024-2025 | Gemtesa, Myfembree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.29 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $58.47 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $45.37 | 2025 | |
| Mylan Specialty L.P. | $44.63 | 2023-2024 | Yupelri |
| Exact Sciences Corporation | $42.57 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $40.85 | 2023 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $35.41 | 2025 | Hetlioz, Fanapt |
| Daiichi Sankyo INC. | $29.52 | 2025 | Injectafer |
| Amgen INC. | $28.60 | 2024-2025 | Otezla, Repatha, Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.90 | 2023-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $21.03 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $19.70 | 2025 | Nexletol |
| Paratek Pharmaceuticals, INC. | $17.27 | 2025 | Nuzyra |
| Glaxosmithkline, LLC. | $15.33 | 2023 | Shingrix |
| Medtronic, INC. | $14.01 | 2024 | Kyphon Express II Kyphopak Tray |
| Phathom Pharmaceuticals, INC. | $13.49 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayce Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.